Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03171519
Other study ID # 1.998.334
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 25, 2017
Est. completion date May 15, 2020

Study information

Verified date February 2021
Source Universidade Federal de Goias
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Introduction: Chronic insomnia is a sleep disorder, characterized by difficulty in initiating and/or maintaining sleep, presence of non-restorative sleep, frequent awakenings or difficulty returning to sleep after each awakening, with a frequency of 3 nights/week, for at least 3 months. Pharmacologic therapy is the most commonly method used for its treatment, however, pharmacotherapy is associated with side effects. Thus, non-pharmacological therapies have been suggested as an alternative. Objective: To verify the effects of exercise associated with acupuncture on chronic insomnia. METHODS: 40 patients with chronic insomnia will be randomly assigned into two groups: CONTROL (n = 20) and ACUPUNCTURE (n = 20). The volunteers of the CONTROL group will be submitted to 12 weeks of aerobic exercise, performed on a treadmill, with frequency of 3 times / week and duration of 50 minutes / day. ACUPUNCTURE volunteers will perform aerobic exercise, following the protocol of the CONTROL group, plus acupuncture therapy once a week. The sleep evaluation will be evaluated by polysomnography and questionnaires. Expected Results: A 12-week combined therapy could potentiate the previously described positive effects of exercise in the treatment of chronic insomnia.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date May 15, 2020
Est. primary completion date November 30, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria: - age 30-60 years; - clinical diagnosis of chronic insomnia according to the DSM-V (performed by a physician specialized in Sleep Medicine); - insomnia complaint at least 3 times a week for at least 3 months; - be physically inactive (exercise less than 2 times a week). Exclusion Criteria: - evidence that insomnia is directly related to medical conditions or side effects os medications; - obstructive sleep apnea syndrome; - ECG abnormalities that prevent physical exercise or use of beta-blockers; - uncontrolled clinical diseases (diabetes, hypertension, cardiovascular, neurological or renal diseases); - use or history of abuse of alcohol or psychoactive substances; - use of sleeping pills>2 times a week; - shift workers.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise
The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
Acupuncture
The ACUPUNCTURE group will participate in an aerobic exercise program following the protocol of the EXERCISE group, plus acupuncture therapy once a week.

Locations

Country Name City State
Brazil Hospital Padre Thiago Jataí Goias

Sponsors (1)

Lead Sponsor Collaborator
Universidade Federal de Goias

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline polysomnography to 12 weeks Polysomnographic recording included an electroencephalogram, an electrooculogram, an electromyogram, and an electrocardiogram. Measurements of air flow (oral and nasal), respiratory effort (thoracic and abdominal), body movement, and oxygen saturation were also taken. The measured variables included total sleep time, sleep efficiency (ratio between total sleep time and total recorded time multiplied by 100), sleep onset latency, wake after sleep onset, arousals, sleep stages (N1, N2 and N3 non-rapid eye movement [non-REM] sleep and REM sleep), latencies for each sleep stage. Two researchers who were blinded to the study design performed the staging and analysed the polysomnographic events using international criteria baseline, week 12
Primary Change from baseline anxiety to 12 weeks Prior sleep state anxiety will be assessed with the State-Trait Anxiety Inventory-STAI,25 the Portuguese version of which was validated by Gorenstein and Andrade.26 This scale encompasses 20 items and provides a one-dimensional measurement of anxiety. The volunteers were instructed to answer it 30 minutes before going to sleep at baseline and at the post-exercise evaluation. baseline, week 12
Primary Change from baseline mood to 12 weeks The POMS questionnaire is an instrument to evaluate the acute profile of mood. It has 65 items and 6 domains: tension-anxiety, depression, anger-hostility, vigour-activity, fatigue, and confusion- bewilderment. The total mood disturbance score is derived by subtracting the vigour-activity score from the the sum of scores from the other subscales 12 weeks
Primary Change from baseline sleep quality to 12 weeks The PSQI assesses sleep quality over a 1-month period. The questionnaire consists of 19 self-rated questions and 5 questions that should be answered by bedmates or roommates. The latter questions are used only for clinical information. The 19 questions are categorized into 7 components, graded on a score that ranges from 0 to 3. The PSQI components are as follows: subjective sleep quality (C1), sleep latency (C2), sleep duration (C3), habitual sleep efficiency (C4), sleep disturbances (C5), use of sleeping medication (C6) and daytime dysfunction (C7). The sum of scores for these 7 components yields one global score, which ranges from 0 to 21, where the highest score indicates worst sleep quality. A global PSQI score greater than 5 indicates major difficulties in at least 2 components or moderate difficulties in more than 3 components. baseline, 12 weeks
Primary Change from baseline quality of life to 12 weeks The SF-36 is a multidimensional questionnaire that covers eight components: physical functioning, role limitations due to physical health problems, role limitations due to emotional health problems, social functioning, vitality, general health perception, body pain, and mental health. All scores ranged from 0 to 100, with a higher score indicating better quality of life baseline, week 12
Primary Change from baseline insomnia to 12 weeks Insomnia Severity Index (ISI) was administrated at baseline and post treatment to assess insomnia-related complaints. It is a short and easy self-applied scale with 7 items scored from 0 to 4, with a total score varying from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia baseline, week 12
Primary Change from baseline sleep diary to 12 weeks The sleep diary was used to evaluate the subjective perceptions of sleep. Participants were instructed to complete the diary every morning after waking for 1 week. The parameters evaluated were sleep onset latency, wake after sleep onset, total time in bed, number of arousals, sleep quality, feeling rested in the morning, and sleep efficiency (calculated retrospectively by the researchers as the ratio of reported total sleep time and reported total time in bed multiplied by 100 [9]). These data were averaged for each volunteer for pre- and post-treatment assessment weeks. baseline, week 12
Secondary Change from baseline serum serotonin to 12 weeks The blood sample will be collected at 8a.m. The serum serotonin dosage will be made by high performance liquid chromatography (HPLC) baseline, 12 weeks
Secondary Change from baseline cortisol to 12 weeks The blood sample will be collected at 8a.m. The cortisol dosage will be made by chemiluminescence. baseline, 12 weeks
Secondary Change from baseline Effort eletrocardiogram test to 12 weeks The test will be performed on a treadmill according to the protocol of Bruce. baseline, 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT02515006 - Impact of Homeopathy for Persistent Insomnia in Patients With Cancer N/A
Recruiting NCT05247697 - Mirtazapine for Chronic Insomnia in Older Adults Phase 1
Active, not recruiting NCT04366284 - Optimizing the Scalability of Evidence-Based Behavioral Sleep Medicine Practices With a Digital Health Platform N/A
Active, not recruiting NCT04350866 - Enhancing Access to Insomnia Care in VA PCMHI Clinics
Recruiting NCT04761796 - Sleep Time and Insomnia Factors Among Professional Flight Members
Completed NCT02688569 - Sleep and Pain Intervention for Chronic Widespread Pain Pilot Study N/A
Completed NCT02236845 - Pilot Study to Clinical Evaluate Lacrima Medical Device in Insomnia Patients N/A
Completed NCT01949389 - Piloting an Internet-based Therapy for Insomnia in a Population of Veterans With Substance Use Disorders N/A
Completed NCT00414102 - Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia. Phase 4
Completed NCT00671294 - Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia. Phase 3
Completed NCT02392000 - Mobile Sleep Intervention for OEF, OIF and OND Veterans N/A
Recruiting NCT04471168 - Interest of Auriculotherapy in the Management of Chronic Insomnia N/A
Completed NCT02774642 - Integrated CBT-I and PE on Sleep and PTSD Outcomes (Impact Study) N/A
Completed NCT02290405 - Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
Completed NCT05618002 - Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients
Completed NCT01995838 - A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia Phase 2
Recruiting NCT05457790 - Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD) N/A
Active, not recruiting NCT02272712 - The Effectiveness of Online Treatment for Insomnia in Cancer Survivors N/A
Completed NCT00915135 - Efficacy and Safety of Ramelteon on Chronic Insomnia Phase 2
Completed NCT04635098 - DexmedetOmidine Complement Treats Chronic insOmnia and Improves Circadian Rhythm (DOCTOR) N/A